As a second-generation EGFR tyrosine kinase inhibitor, Dacomitinib plays a key role in the treatment of non-small cell lung cancer, and the Laos Dabear version, as a compliant generic, provides a more accessible and effective option for patients worldwide.
What are the purchasing channels for the Laos Dabear version of Dacomitinib?
The Laos Dabear version of Dacomitinib is available in specifications of 15mg*30 tablets and 45mg*30 tablets. For specific purchase methods, we recommend adding our professional customer service for detailed consultation.
Indications and standard dosage of Dacomitinib
According to the drug label, the clear indication for Dacomitinib is: treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring EGFR gene exon 19 deletions or exon 21 L858R substitution mutations. This indication covers the most common EGFR sensitizing mutations, providing a precision treatment option for patients with advanced lung cancer. Regarding dosage and administration, the recommended standard dose is 45mg of Dacomitinib taken orally once daily. Patients should take it at the same time each day to maintain consistent blood concentrations. It is important to note that if a patient vomits or misses a dose after taking the medication, they should not take a replacement or double dose, but should resume the next scheduled dose as usual. During treatment, physicians should consider dose interruption, reduction, or permanent discontinuation based on the patient's tolerability and severity of adverse reactions. Dacomitinib is manufactured by Pfizer and marketed under the brand name Vizimpro film-coated tablets, each pack containing 30 tablets of 45mg. Prior to using this drug, the patient's EGFR mutation status must be confirmed using an approved test to ensure that the drug is used only in patients with the corresponding mutations, achieving the best benefit-risk ratio.
Warnings and precautions for using Dacomitinib
During treatment with Dacomitinib (Vizimpro, dacomitinib), patients and healthcare providers should pay close attention to warnings and precautions for several serious adverse events. First, interstitial lung disease (ILD) is a serious and potentially life-threatening adverse reaction. If ILD is confirmed, Vizimpro must be permanently discontinued and treatment should not be resumed. Second, diarrhea is very common and can lead to severe dehydration and electrolyte imbalance, even death. Depending on the severity of diarrhea, dose interruption and reduction of Vizimpro should be considered, along with active fluid replacement and antidiarrheal symptomatic treatment. Third, dermatologic adverse reactions, including rash, dry skin, and paronychia, also require high attention. Based on the severity of skin reactions, dose interruption and reduction should be considered, and patients should be advised to use daily moisturizers, sunscreen, and protective clothing. Fourth, embryo-fetal toxicity: Vizimpro may cause fetal harm. Therefore, females with reproductive potential must use effective contraception during treatment and for at least 17 days after the last dose. Additionally, regarding use in specific populations, breastfeeding is not recommended as it is unknown whether the drug is excreted in human milk. Patients should fully inform their physician of all medical history, including lung disease or frequent diarrhea.
